A healthtech founder came to me frustrated.

Strong product.
Clear ROI.
Great demos.

Still, deals dragged.

Pilots stalled.
Procurement slowed.
Approvals never fully landed.

From the outside, it looked like a sales problem.

It wasn’t.

It was a risk problem.

In healthcare, no one buys on value alone.

They approve based on exposure.

In this case, the founder was selling to a “buyer.”

But the real decision path included:

Clinical leadership.
Compliance.
IT and security.
Finance.

Each asking a different question.

And none aligned.

So the deal kept resetting.

Here’s what we changed:

1. Mapped the full decision path

Not just the champion.

Every stakeholder with veto power.

2. Tightened ICP around workflows

Not “health systems.”

Specific use cases with clear data constraints.

3. Rebuilt the narrative

→ Clinical: patient impact and safety
→ Compliance: privacy and auditability
→ IT: integration and security
→ Finance: measurable outcomes

4. Sequenced proof the right way

Not ROI first.

Risk containment first.

Then value.

The result?

Faster internal alignment.
Fewer stalled pilots.
Deals moving with momentum.

In healthcare, you don’t win by being better.

You win by being safer to approve.

If your pipeline feels slow,
it’s probably not demand.

It’s misaligned risk narratives.

If you want,
we can map your stakeholder journey
and identify the blockers slowing adoption.